Efficacy and safety of 1064-nm fractional picosecond laser for the treatment of postmastectomy scars in transgender men: A randomized controlled trial
3
Issued Date
2024-01-01
Resource Type
ISSN
01968092
eISSN
10969101
Scopus ID
2-s2.0-85186876150
Pubmed ID
38436118
Journal Title
Lasers in Surgery and Medicine
Rights Holder(s)
SCOPUS
Bibliographic Citation
Lasers in Surgery and Medicine (2024)
Suggested Citation
Rutnin S., Yongpisarn T., Sakpuwadol N., Namasondhi A., Pomsoong C., Rattananukrom T., Thadanipon K. Efficacy and safety of 1064-nm fractional picosecond laser for the treatment of postmastectomy scars in transgender men: A randomized controlled trial. Lasers in Surgery and Medicine (2024). doi:10.1002/lsm.23775 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/97587
Title
Efficacy and safety of 1064-nm fractional picosecond laser for the treatment of postmastectomy scars in transgender men: A randomized controlled trial
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
Objectives: Subcutaneous mastectomy is a crucial component of gender affirmation therapy for transgender men (TM), but the scars that result from this procedure can frequently impair their quality of life. This study aimed to assess the efficacy and safety of 1064-nm fractional picosecond laser (FxPico) treatment for hypertrophic and atrophic postmastectomy scars in TM. Methods: Twenty-two patients with a total of 35 pairs of bilateral symmetric mastectomy scars were enrolled. One of each pair of symmetric scars was randomly assigned to receive four FxPico treatments at 4-week intervals. All scars were evaluated using the modified Vancouver Scar Scale (mVSS) and three-dimensional imaging for scar roughness, melanin index, and hemoglobin index before each treatment session and at 1, 3, and 6 months following the last treatment. Additionally, participant-rated scar satisfaction (PSS) and scar improvement (Global Assessment Score, GAS), as well as adverse events were recorded. Results: During the 6-month follow-up period after the end of laser treatment sessions, the treated scars showed significant reductions in the mVSS compared to the untreated controls (p < 0.001), whereas the melanin index and hemoglobin index were not significantly different. Subgroup analysis of hypertrophic scars demonstrated statistically significant reductions in mVSS at 1 (p = 0.003) and 3 months (p = 0.041) after the end of laser treatments. PSS was significantly higher on the laser-treated scars than the controls (p = 0.008), and a participant-rated GAS of 2.95 ± 0.65 was found. There were no serious adverse events reported. Conclusions: 1064-nm FxPico could be utilized to treat mastectomy scars among TM, particularly the hypertrophic type.